Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1152826 | 1.00 | SLC6A4 (0.37) | SLC6A4SLC6A3 | |
| SCHEMBL25971172 | 1.00 | SLC6A4 (0.37) | SLC6A4SLC6A3 | |
| SCHEMBL1153662 | 0.97 | SLC6A4 (0.40) | SLC6A4SLC6A3 | |
| SCHEMBL1660968 | 0.97 | SLC6A4 (0.40) | SLC6A4SLC6A3 | |
| SCHEMBL7677226 | 0.97 | SLC6A4 (0.40) | SLC6A4SLC6A3 | |
| SCHEMBL7101757 | 0.97 | SLC6A4 (0.40) | SLC6A4SLC6A3 | |
| SCHEMBL7101798 | 0.95 | SLC6A4 (0.33) | SLC6A4SLC6A3 | |
| SCHEMBL1153867 | 0.95 | SLC6A4 (0.33) | SLC6A4SLC6A3 | |
| SCHEMBL1152703 | 0.78 | — | — | |
| SCHEMBL15756034 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| US-20160045531-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2016-02-18 | — | — | US | disclosed |
| EP-1958940-B1 | CONDENSATION REACTION BY METAL CATALYST | TAKASAGO PERFUMERY CO LTD (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-20110098479-A1 | CONDENSATION REACTION BY METAL CATALYST | MASHIMA KAZUSHI | 2011-04-28 | — | — | US | disclosed |
| US-7888513-B2 | Condensation reaction by metal catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-02-15 | — | — | US | disclosed |
| US-20090198070-A1 | Condensation Reaction by Metal Catalyst | OSAKA UNIVERSITY (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-1958940-A1 | CONDENSATION REACTION BY METAL CATALYST | Takasago International Corporation (JP) | 2008-08-20 | — | — | EP | disclosed |
| CN-1231456-C | Process for preparing optically active cyclopropyl carboxylic acid derivative | SUMITOMO CHEMICAL CO (JP) | 2005-12-14 | — | — | CN | disclosed |
| CN-1480448-A | Process for preparing optically active cyclopropyl carboxylic acid derivative | ס�ѻ�ѧ��ҵ��ʽ���� | 2004-03-10 | — | — | CN | disclosed |
| CN-1134422-C | Optically active bisoxazoline compounds, process for their preparation and their use | ������������ʽ���� | 2004-01-14 | — | — | CN | disclosed |
| EP-0942010-B1 | Transition metal compounds, catalyst components and catalysts for olefin polymerization, and process for producing olefinic polymer | SUMITOMO CHEMICAL CO (JP) | 2003-06-18 | — | — | EP | disclosed |
| US-6500909-B2 | CONTAINING NICKEL, PALLADIUM, RHODIUM, RUTHENIUM, OR COBALT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-31 | — | — | US | disclosed |
| US-6410741-B1 | INSECTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| US-20010027162-A1 | Transition metal compound, catalyst component for olefin polymerization, catalyst for olefin polymerization, and process for producing olefinic polymer | HIRAHATA WATARU (JP) | 2001-10-04 | — | — | US | disclosed |
| US-6072081-A | Optically active bisoxazoline compounds, production and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-06-06 | — | — | US | disclosed |
| EP-0942010-A1 | Transition metal compounds, catalyst components and catalysts for olefin polymerization, and process for producing olefinic polymers | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-09-15 | — | — | EP | disclosed |
| CN-1210858-A | Optically active bisoxazoline compounds, process for their preparation and their use | SUMITOMO CHEMICAL CO (JP) | 1999-03-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | SLC6A4 1561/4885SLC6A3 3086/4885 |
| US-20110098479-A1 | CONDENSATION REACTION BY METAL CATALYST | C9, CBR3, C1R | SLC6A4 3420/4885SLC6A3 4490/4885 |
| US-20160045531-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, ASH1L, CARM1 | SLC6A4 4548/4885SLC6A3 4259/4885 |
| US-20090198070-A1 | Condensation Reaction by Metal Catalyst | C9, CBR3, C1R | SLC6A4 3420/4885SLC6A3 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.